A novel targeting therapy of malignant mesothelioma using anti-podoplanin antibody

Journal of Immunology

Volumn 190, Issue 12, 2013, Pages 6239-6249

  Abe, Shinji ^a   Morita, Yuki ^b   Kaneko, Mika Kato ^c   Hanibuchi, Masaki ^a   Tsujimoto, Yuta ^c   Goto, Hisatsugu ^a   Kakiuchi, Soji ^a   Aono, Yoshinori ^a   Huang, Jun ^a   Sato, Seidai ^a   Kishuku, Masatoshi ^b   Taniguchi, Yuki ^b   Azuma, Mami ^a   Kawazoe, Kazuyoshi ^b   Sekido, Yoshitaka ^d   Yano, Seiji ^e   Akiyama, Shin Ichi ^d   Sone, Saburo ^a   Minakuchi, Kazuo ^b   Kato, Yukinari ^c   Nishioka, Yasuhiko ^a   more..

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b TOKUSHIMA UNIVERSITY HOSPITAL   (Japan)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d AICHI CANCER CENTER HOSPITAL   (Japan)

^e KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY NZ 1; MONOCLONAL ANTIBODY NZ 8; PODOPLANIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER TISSUE; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DRUG POTENCY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MONONUCLEAR CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SCID MOUSE; SPLEEN CELL; TUMOR CELL LINE; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; MALE; MEMBRANE GLYCOPROTEINS; MESOTHELIOMA; MICE; MICE, SCID; PLEURAL NEOPLASMS; RATS; RATS, WISTAR; RECOMBINANT FUSION PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84879077572     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1300448     Document Type: Article

References (53)

1. Robinson, B. W., and R. A. Lake. 2005. Advances in malignant mesothelioma. N. Engl. J. Med. 353: 1591-1603. (Pubitemid 41434638)
2. Pelucchi, C., M. Malvezzi, C. La Vecchia, F. Levi, A. Decarli, and E. Negri.The Mesothelioma epidemic in Western Europe: an update. Br. J. Cancer 90: 1022-1024.
3. Murayama, T., K. Takahashi, Y. Natori, and N. Kurumatani. 2006. Estimation of future mortality from pleural malignant mesothelioma in Japan based on an agecohort model. Am. J. Ind. Med. 49: 1-7. (Pubitemid 43083291)
4. Ray, M., and H. L. Kindler. 2009. Malignant pleural mesothelioma: an update on biomarkers and treatment. Chest 136: 888-896.
5. Vogelzang, N. J., J. J. Rusthoven, J. Symanowski, C. Denham, E. Kaukel, P. Ruffie, U. Gatzemeier, M. Boyer, S. Emri, C. Manegold, et al. 2003. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 21: 2636-2644. (Pubitemid 46606305)
6. Scherpereel, A., P. Astoul, P. Baas, T. Berghmans, H. Clayson, P. de Vuyst, H. Dienemann, F. Galateau-Salle, C. Hennequin, G. Hillerdal, et al European Respiratory Society/European Society of Thoracic Surgeons Task Force. 2010. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur. Respir. J. 35: 479-495.
7. Inamoto, T., T. Yamada, K. Ohnuma, S. Kina, N. Takahashi, T. Yamochi, S. Inamoto, Y. Katsuoka, O. Hosono, H. Tanaka, et al. 2007. Humanized anti- CD26 monoclonal antibody as a treatment for malignant mesothelioma tumors. Clin. Cancer Res. 13: 4191-4200. (Pubitemid 47105983)
8. Inami, K., M. Abe, K. Takeda, Y. Hagiwara, M. Maeda, T. Segawa, M. Suyama, S. Watanabe, and O. Hino. 2010. Antitumor activity of anti-C-ERC/mesothelin monoclonal antibody in vivo. Cancer Sci. 101: 969-974.
9. Krug, L. M., T. Dao, A. B. Brown, P. Maslak, W. Travis, S. Bekele, T. Korontsvit, V. Zakhaleva, J. Wolchok, J. Yuan, et al. 2010. WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and nonsmall cell lung cancer. Cancer Immunol. Immunother. 59: 1467-1479.
10. Hassan, R., S. J. Cohen, M. Phillips, I. Pastan, E. Sharon, R. J. Kelly, C. Schweizer, S. Weil, and D. Laheru. 2010. Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelinexpressing cancers. Clin. Cancer Res. 16: 6132-6138.
11. Kato, Y., N. Fujita, A. Kunita, S. Sato, M. Kaneko, M. Osawa, and T. Tsuruo. 2003. Molecular identification of Aggrus/T1alpha as a platelet aggregation-inducing factor expressed in colorectal tumors. J. Biol. Chem. 278: 51599-51605. (Pubitemid 38020404)
12. Kaneko, M. K., Y. Kato, T. Kitano, and M. Osawa. 2006. Conservation of a platelet activating domain of Aggrus/podoplanin as a platelet aggregation-inducing factor. Gene 378: 52-57. (Pubitemid 44108465)
13. Kaneko, M., Y. Kato, A. Kunita, N. Fujita, T. Tsuruo, and M. Osawa. 2004. Functional sialylated O-glycan to platelet aggregation on Aggrus (T1alpha/Podoplanin) molecules expressed in Chinese hamster ovary cells. J. Biol. Chem. 279: 38838-38843. (Pubitemid 39296043)
14. Hatakeyama, K., M. K. Kaneko, Y. Kato, T. Ishikawa, K. Nishihira, Y. Tsujimoto, Y. Shibata, Y. Ozaki, and Y. Asada. 2012. Podoplanin expression in advanced atherosclerotic lesions of human aortas. Thromb. Res. 129: e70-e76.
15. Breiteneder-Geleff, S., K. Matsui, A. Soleiman, P. Meraner, H. Poczewski, R. Kalt, G. Schaffner, and D. Kerjaschki. 1997. Podoplanin, novel 43-kd membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis. Am. J. Pathol. 151: 1141-1152. (Pubitemid 27424324)
16. Breiteneder-Geleff, S., A. Soleiman, H. Kowalski, R. Horvat, G. Amann, E. Kriehuber, K. Diem, W. Weninger, E. Tschachler, K. Alitalo, and D. Kerjaschki. 1999. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am. J. Pathol. 154: 385-394. (Pubitemid 29094089)
17. Vanderbilt, J. N., L. Allen, R. F. Gonzalez, Z. Tigue, J. Edmondson, D. Ansaldi, A. M. Gillespie, and L. G. Dobbs. 2008. Directed expression of transgenes to alveolar type I cells in the mouse. Am. J. Respir. Cell Mol. Biol. 39: 253-262.
18. Kimura, N., and I. Kimura. 2005. Podoplanin as a marker for mesothelioma. Pathol. Int. 55: 83-86. (Pubitemid 40343728)
19. Kato, Y., M. Kaneko, M. Sata, N. Fujita, T. Tsuruo, and M. Osawa. 2005. Enhanced expression of Aggrus (T1alpha/podoplanin), a platelet-aggregation- inducing factor in lung squamous cell carcinoma. Tumour Biol. 26: 195-200. (Pubitemid 41379745)
20. Kato, Y., I. Sasagawa, M. Kaneko, M. Osawa, N. Fujita, and T. Tsuruo. 2004. Aggrus: a diagnostic marker that distinguishes seminoma from embryonal carcinoma in testicular germ cell tumors. Oncogene 23: 8552-8556. (Pubitemid 39540806)
21. Suzuki, H., Y. Kato, M. K. Kaneko, Y. Okita, H. Narimatsu, and M. Kato. 2008. Induction of podoplanin by transforming growth factor-beta in human fibrosarcoma. FEBS Lett. 582: 341-345.
22. Mishima, K., Y. Kato, M. K. Kaneko, R. Nishikawa, T. Hirose, and M. Matsutani. 2006. Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression. Acta Neuropathol. 111: 483-488.
23. Wicki, A., F. Lehembre, N. Wick, B. Hantusch, D. Kerjaschki, and G. Christofori. 2006. Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell 9: 261-272.
24. Martín-Villar, E., B. Fernández-Muñoz, M. Parsons, M. M. Yurrita, D. Megías, E. Pérez-Gómez, G. E. Jones, and M. Quintanilla. 2010. Podoplanin associates with CD44 to promote directional cell migration. Mol. Biol. Cell 21: 4387-4399.
25. Martín-Villar, E., D. Megías, S. Castel, M. M. Yurrita, S. Vilaró, and M. Quintanilla. 2006. Podoplanin binds ERM proteins to activate RhoA and promote epithelial-mesenchymal transition. J. Cell Sci. 119: 4541-4553. (Pubitemid 44830653)
26. Kunita, A., T. G. Kashima, Y. Morishita, M. Fukayama, Y. Kato, T. Tsuruo, and N. Fujita. 2007. The platelet aggregation-inducing factor aggrus/podoplanin promotes pulmonary metastasis. Am. J. Pathol. 170: 1337-1347. (Pubitemid 47339340)
27. Kato, Y., M. K. Kaneko, A. Kunita, H. Ito, A. Kameyama, S. Ogasawara, N. Matsuura, Y. Hasegawa, K. Suzuki-Inoue, O. Inoue, et al. 2008. Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2. Cancer Sci. 99: 54-61. (Pubitemid 350239031)
28. Tsuneki, M., S. Maruyama, M. Yamazaki, J. Cheng, and T. Saku. 2012. Podoplanin expression profiles characteristic of odontogenic tumor-specific tissue architectures. Pathol. Res. Pract. 208: 140-146.
29. Yuan, P., S. Temam, A. El-Naggar, X. Zhou, D. D. Liu, J. J. Lee, and L. Mao. 2006. Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. Cancer 107: 563-569. (Pubitemid 44107217)
30. Hoshino, A., G. Ishii, T. Ito, K. Aoyagi, Y. Ohtaki, K. Nagai, H. Sasaki, and A. Ochiai. 2011. Podoplanin-positive fibroblasts enhance lung adenocarcinoma tumor formation: podoplanin in fibroblast functions for tumor progression. Cancer Res. 71: 4769-4779.
31. Kato, Y., M. K. Kaneko, A. Kuno, N. Uchiyama, K. Amano, Y. Chiba, Y. Hasegawa, J. Hirabayashi, H. Narimatsu, K. Mishima, and M. Osawa. 2006. Inhibition of tumor cell-induced platelet aggregation using a novel anti-podoplanin antibody reacting with its platelet-aggregation-stimulating domain. Biochem. Biophys. Res. Commun. 349: 1301-1307. (Pubitemid 44416399)
32. Ogasawara, S., M. K. Kaneko, J. E. Price, and Y. Kato. 2008. Characterization of anti-podoplanin monoclonal antibodies: critical epitopes for neutralizing the interaction between podoplanin and CLEC-2. Hybridoma (Larchmt) 27: 259-267.
33. Kato, Y., G. Vaidyanathan, M. K. Kaneko, K. Mishima, N. Srivastava, V. Chandramohan, C. Pegram, S. T. Keir, C. T. Kuan, D. D. Bigner, and M. R. Zalutsky. 2010. Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas. Nucl. Med. Biol. 37: 785-794.
34. Jiang, X. R., A. Song, S. Bergelson, T. Arroll, B. Parekh, K. May, S. Chung, R. Strouse, A. Mire-Sluis, and M. Schenerman. 2011. Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat. Rev. Drug Discov. 10: 101-111.
35. Kawaguchi, K., H. Murakami, T. Taniguchi, M. Fujii, S. Kawata, T. Fukui, Y. Kondo, H. Osada, N. Usami, K. Yokoi, et al. 2009. Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells. Carcinogenesis 30: 1097-1105.
36. Yokoyama, A., N. Kohno, S. Fujino, H. Hamada, Y. Inoue, S. Fujioka, and K. Hiwada. 1994. Origin of heterogeneity of interleukin-6 (IL-6) levels in malignant pleural effusions. Oncol. Rep. 1: 507-511. (Pubitemid 2069996)
37. Taniguchi, T., S. Karnan, T. Fukui, T. Yokoyama, H. Tagawa, K. Yokoi, Y. Ueda, T. Mitsudomi, Y. Horio, T. Hida, et al. 2007. Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32. Cancer Sci. 98: 438-446. (Pubitemid 46195618)
38. Giovannetti, E., P. A. Zucali, Y. G. Assaraf, L. G. Leon, K. Smid, C. Alecci, F. Giancola, A. Destro, L. Gianoncelli, E. Lorenzi, et al. 2011. Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin. Br. J. Cancer 105: 1542-1553.
39. Li, Q., W. Wang, T. Yamada, K. Matsumoto, K. Sakai, Y. Bando, H. Uehara, Y. Nishioka, S. Sone, S. Iwakiri, et al. 2011. Pleural mesothelioma instigates tumor-associated fibroblasts to promote progression via a malignant cytokine network. Am. J. Pathol. 179: 1483-1493.
40. Wang, W., Y. Nishioka, S. Ozaki, A. Jalili, S. Abe, S. Kakiuchi, M. Kishuku, K. Minakuchi, T. Matsumoto, and S. Sone. 2009. HM1.24 (CD317) is a novel target against lung cancer for immunotherapy using anti-HM1.24 antibody. Cancer Immunol. Immunother. 58: 967-976.
41. Kuramoto, T., H. Goto, A. Mitsuhashi, S. Tabata, H. Ogawa, H. Uehara, A. Saijo, S. Kakiuchi, Y. Maekawa, K. Yasutomo, et al. 2012. Dll4-Fc, an inhibitor of Dll4- notch signaling, suppresses liver metastasis of small cell lung cancer cells through the downregulation of the NF-kB activity. Mol. Cancer Ther. 11: 2578-2587.
42. Kishuku, M., Y. Nishioka, S. Abe, J. Kishi, H. Ogino, Y. Aono, M. Azuma, K. Kinoshita, R. Batmunkh, H. Makino, et al. 2009. Expression of soluble vascular endothelial growth factor receptor-1 in human monocyte-derived mature dendritic cells contributes to their antiangiogenic property. [Published erratum appears in 2010. J. Immunol. 185: 2630.] J. Immunol. 183: 8176-8185.
43. Wang, W., Y. Nishioka, S. Ozaki, A. Jalili, V. K. Verma, M. Hanibuchi, S. Abe, K. Minakuchi, T. Matsumoto, and S. Sone. 2009. Chimeric and humanized anti-HM1.24 antibodies mediate antibody-dependent cellular cytotoxicity against lung cancer cells. Lung Cancer 63: 23-31.
44. Nishioka, Y., N. Nishimura, Y. Suzuki, and S. Sone. 2001. Human monocytederived and CD83(+) blood dendritic cells enhance NK cell-mediated cytotoxicity. Eur. J. Immunol. 31: 2633-2641. (Pubitemid 32898730)
45. Zou, P., S. Xu, S. P. Povoski, A. Wang, M. A. Johnson, E. W. Martin, Jr., V. Subramaniam, R. Xu, and D. Sun. 2009. Near-infrared fluorescence labeled anti-TAG-72 monoclonal antibodies for tumor imaging in colorectal cancer xenograft mice. Mol. Pharm. 6: 428-440.
46. Chu, A. Y., L. A. Litzky, T. L. Pasha, G. Acs, and P. J. Zhang. 2005. Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma. Mod. Pathol. 18: 105-110. (Pubitemid 40128102)
47. Ordóñez, N. G. 2006. The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study. Mod. Pathol. 19: 34-48. (Pubitemid 43250977)
48. Chirieac, L. R., G. S. Pinkus, J. L. Pinkus, J. Godleski, D. J. Sugarbaker, and J. M. Corson. 2011. The immunohistochemical characterization of sarcomatoid malignant mesothelioma of the pleura. Am. J. Cancer Res. 1: 14-24.
49. Yaziji, H., H. Battifora, T. S. Barry, H. C. Hwang, C. E. Bacchi, M. W. McIntosh, S. J. Kussick, and A. M. Gown. 2006. Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity. Mod. Pathol. 19: 514-523.
50. Raica, M., A. M. Cimpean, and D. Ribatti. 2008. The role of podoplanin in tumor progression and metastasis. Anticancer Res. 28: 2997-3006.
51. Bergman, I., P. H. Basse, M. A. Barmada, J. A. Griffin, and N. K. Cheung. 2000. Comparison of in vitro antibody-targeted cytotoxicity using mouse, rat and human effectors. Cancer Immunol. Immunother. 49: 259-266. (Pubitemid 30484833)
52. Caragine, T. A., M. Imai, A. B. Frey, and S. Tomlinson. 2002. Expression of rat complement control protein Crry on tumor cells inhibits rat natural killer cellmediated cytotoxicity. Blood 100: 3304-3310. (Pubitemid 35217081)
53. Rudnick, S. I., J. Lou, C. C. Shaller, Y. Tang, A. J. Klein-Szanto, L. M. Weiner, J. D. Marks, and G. P. Adams. 2011. Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. Cancer Res. 71: 2250-2259.